IonOptix产品代理
IonOptix产品代理
作为一家科学家公司，IonOptix 热衷于为我们的同事提供高速定量荧光、肌肉力学和组织工程的创新研究解决方案。
IonOptix 在我们位于马萨诸塞州的国际总部生产一系列用于荧光离子定量和肌肉力学测量的系统。我们的目标是生产出价格在单个研究人员范围内的最佳系统。
IonOptix Corporation 由 Douglas Tillotson 博士于 1990 年成立，其目标是开发、制造和销售使用荧光指示剂量化细胞离子水平的完整系统。这些初始系统是只有一对激励滤波器的视频速率斩波系统。它们是我们 HyperSwitch 光源的先驱。 1992 年，Doug 开始与波士顿一家领先的心脏病学实验室进行专业合作，该实验室的心脏研究工作主要涉及整个器官的研究。通过这次合作，开发了一个系统来同时记录单个心肌细胞的钙水平和细胞长度（通过数字化模拟边缘检测器的输出获得）。基于软件的边缘检测系统的开发始于 1995 年，心脏研究界的销售额现在占 IonOptix 业务的 3/4 以上。
1998 年，IonOptix 公司获得了 NIH SBIR 项目的资助，用于开发新的心脏收缩记录仪器。实时肌节长度记录诞生于这项工作，并产生了许多其他进步，包括开发了 MyoPacer，这是一种用于显微镜安装的细胞室中肌细胞的独立场刺激器。近年来的进一步发展包括更快的 CCD 相机、用于防止培养细胞去分化的 C-Pace 系统以及软件控制和分析的进步。
2008 年，IonOptix Corporation 与 Red Box Direct Ltd. 在美国成立了 IonOptix LLC，在欧洲成立了 IonOptix Limited 作为扩展计划的一部分，以发展我们的业务并为我们的客户提供更好的本地支持。 2015 年，Doug 卸任 CEO，Tom Udale 接任。那年晚些时候，我们搬到了位于马萨诸塞州韦斯特伍德的新总部，并扩大了我们的员工队伍，包括更多的应用程序支持人员。 2015 年底，IonOptix 首席安全官 Michiel Helmes 在荷兰创建了 CytoCypher BV，开始与 IonOptix 合作开发我们核心钙和收缩系统的更高通量版本。 CytoCypher 后来于 2018 年底与 IonOptix 合并。在同一时期，IonOptix 分别于 2017 年 4 月和 2019 年 4 月获得了 NIH SBIR I 和 II 期资助，用于将这种更高通量系统的商业化。
截至 2019 年，我们现在是一家拥有 30 多名员工的公司，在北美、欧洲和亚洲的办事处为全球 500 多个临床前研究实验室提供服务。我们的目标是通过开发创新工具和提供世界一流的支持，使我们的客户能够做出重大的科学发现。
Inspired By Innovation & Discovery
As a company of scientists, IonOptix is passionate about providing our colleagues with innovative research solutions for high speed quantitative fluorescence, muscle mechanics, and tissue engineering.
From our international headquarters in Massachusetts, IonOptix produces a range of systems for fluorescent ion quantitation and muscle mechanics measurements. Our goal is to produce the best possible systems priced within reach of the individual researcher.
IonOptix Corporation was formed in 1990 by Dr. Douglas Tillotson, with the goal of developing, manufacturing and selling complete systems for quantifying cellular ion levels
using fluorescence indicators. These initial systems were video-rate chopper systems with only a single pair of excitation filters. They were the forerunners of our HyperSwitch light source. In 1992, Doug began a professional collaboration with a leading Boston cardiology lab whose heart research efforts principally involved whole organ studies. Through this collaboration, a system was developed to simultaneously record the calcium level and the cell length of a single cardiac myocyte (obtained by digitizing the output of an analog edge detector). Development of the software-based edge detection system was begun in 1995 and sales to the heart research community now account for over 3/4 of the IonOptix business.
In 1998 IonOptix Corporation received grant support from the NIH SBIR program for developing new instrumentation for cardiac contractility recording. Real-time sarcomere length recording was born from this effort and numerous other advances resulted including the development of the MyoPacer, a stand-alone field stimulator for myocytes in a microscope-mounted cell chamber. Further developments in recent years include faster CCD cameras, the C-Pace system for preventing de-differentiation in cultured cells and advances in software control and analysis.
In 2008 IonOptix Corporation, with Red Box Direct Ltd., formed IonOptix LLC in the US and IonOptix Limited in Europe as part of an expansion plan to grow our business and provide better
local support to our customers. In 2015, Doug stepped down as CEO and Tom Udale took the reigns. Later that year, we moved to our new headquarters in Westwood, MA and expanded our staff to include additional Applications support staff. In late 2015, IonOptix CSO, Michiel Helmes, created CytoCypher BV in the Netherlands to begin development, in collaboration with IonOptix, of a higher throughput version of our core calcium and contractility system. CytoCypher later merged with IonOptix in late 2018. During this same time period, IonOptix was awarded NIH SBIR phase I and II grants for commercialization of this higher throughput system in April 2017 and April 2019, respectively.
As of 2019, we are now a company of over 30 employees, serving over 500 preclinical research labs worldwide from offices in North America, Europe, and Asia. Our goal is to enable our customers to make significant scientific discoveries by developing innovative tools and providing world-class support.
